<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137885">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936181</url>
  </required_header>
  <id_info>
    <org_study_id>SB2-G31-RA</org_study_id>
    <nct_id>NCT01936181</nct_id>
  </id_info>
  <brief_title>A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate
      the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to Remicade in
      subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX)
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>American College of Rheumatology 20% response criteria (ACR20)</measure>
    <time_frame>Week 30</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20</measure>
    <time_frame>Week 54</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 50% response criteria (ACR50)</measure>
    <time_frame>Week 30, Week 54</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity score based on a 28 joint count (DAS28)</measure>
    <time_frame>Week 30, Week 54</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">584</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SB2 (proposed biosimilar to inflixmab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade (infliximab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remicade (infliximab)</intervention_name>
    <arm_group_label>Remicade (infliximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB2 (proposed biosimilar to infliximab)</intervention_name>
    <arm_group_label>SB2 (proposed biosimilar to inflixmab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6
             months

          -  Have moderate to severe active disease despite MTX therapy defined as having more
             than or equal to six swollen joints and more than or equal to six tender joints and
             either erythrocyte sedimentation rate (ESR, Westergren) ≥ 28 mm/h or serum C-reactive
             protein ≥ 1.0 mg/dL

          -  Must have been treated with MTX for at least 6 months prior to Randomisation and on a
             stable dose of MTX 10-25 mg/week given at least 4 weeks prior to Screening

          -  Female subjects who are not pregnant or nursing at Screening and who are not planning
             to become pregnant from Screening until 6 months after the last dose of
             investigational product

        Exclusion Criteria:

          -  Have been treated previously with any biological agents including any tumour necrosis
             factor inhibitor

          -  Have a known hypersensitivity to human immunoglobulin proteins or other components of
             Remicade or SB2

          -  Have a positive serological test for hepatitis B or hepatitis C or have a known
             history of infection with human immunodeficiency virus

          -  Have a current diagnosis of active tuberculosis

          -  Have had a serious infection or have been treated with intravenous antibiotics for an
             infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.

          -  Have any of the following conditions

               1. Other inflammatory or rheumatic diseases.

               2. History of any malignancy within the previous 5 years prior to Screening

               3. History of lymphoproliferative disease including lymphoma.

               4. History of congestive heart failure

               5. Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).

               6. History of demyelinating disorders.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Smolen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hristo Botev Str.</city>
        <state>Sliven</state>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Santariskiu</city>
        <state>Vilnius</state>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Biosimilar</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
